| Financial Highlights | Financial Review | | Management’s Report | Audit Committee’s Report | | Independent Auditors’ Report | Financial Statements | Notes to Financial Statements | | Directors, Committees, and Officers | | Corporate and Shareholder Information |	| Consolidated Income | | Consolidated Balance Sheet | | Consolidated Shareholder’s Equity | | Consolidated Cash Flows | | Segment Information | Geographic Data | | Quarterly Data | Financial Summary |

Quarterly Consolidated Financial Data

Pfizer Inc and Subsidiary Companies   Quarter   (millions of dollars, except per share data)   First   Second   Third   Fourth   Year  1997                     Net sales  $ 3,002  $ 2,854  $ 2,999  $ 3,333  $ 12,188  Alliance revenue   (1)   59   95   163   316  Total revenues   3,001   2,913   3,094   3,496   12,504  Costs and expenses                     Cost of sales   545   510   546   673   2,274  Selling, informational and administrative expenses   1,114   1,245   1,186   1,411   4,956  Research and development expenses   413   461   477   577   1,928  Other deductions — net   67   61   73   57   258  Income before provision for taxes on income and minority interests   862   636   812   778   3,088  Provision for taxes on income   259   175   213   218   865  Minority interests   1   4   3   2   10  Net income  $ 602  $ 457  $ 596  $ 558  $ 2,213  Earnings per common share — basic*  $ .48  $ .36  $ .48  $ .44  $ 1.76  Earnings per common share — diluted*  $ .46  $ .35  $ .46  $ .43  $ 1.70  Cash dividends paid per common share  $ .17  $ .17  $ .17  $ .17  $ .68  Stock prices**                     High  $ 49 1/2  $ 61 9/16  $ 64 3/4  $ 80   $ 80  Low  $ 40 5/16  $ 41 1/2  $ 51 1/16  $ 59 7/16  $ 40 5/16 1996                     Net sales  $ 2,682  $ 2,661  $ 2,803  $ 3,160  $ 11,306  Costs and expenses                     Cost of sales   513   521   522   620   2,176  Selling, informational and administrative expenses   994   1,083   1,040   1,249   4,366  Research and development expenses   366   422   406   490   1,684  Other deductions — net   57   61   86   72   276  Income before provision for taxes on income and minority interests   752   574   749   729   2,804  Provision for taxes on income   233   178   232   226   869  Minority interests   2   2   3   (1)   6  Net income  $ 517  $ 394  $ 514  $ 504  $ 1,929  Earnings per common share — basic*  $ .42  $ .31  $ .41  $ .41  $ 1.55  Earnings per common share — diluted*  $ .40  $ .31  $ .40  $ .39  $ 1.50  Cash dividends paid per common share  $ .15  $ .15  $ .15  $ .15  $ .60  Stock prices**                     High  $ 35 3/8  $ 38 11/16  $ 39 3/4  $ 45 5/8  $ 45 5/8 Low  $ 30 1/16  $ 31 7/16  $ 32 13/16  $ 38 3/4  $ 30 1/16  * Earnings per common share have been recomputed for the adoption of SFAS No. 128. For additional details,    see note 1-H, “Significant Accounting Policies — Earnings Per Common Share.” ** As reported in The Wall Street Journal.All figures have been adjusted for the 1997 two-for-one stock split.    As of January 31, 1998 there were 87,198 record holders of our common stock (symbol PFE).

	Advisory Information for Investors
	Copyright © 1997, 1998 Pfizer Inc All rights reserved.